Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

EluNIR Ridaforolimus Eluting Coronary Stent System in Patients at High Bleeding Risk (HBR)- EluNIR HBR Study

NCT03877848 is registered in ClinicalTrials.gov with Medinol Ltd. as lead sponsor.

NCT NCT03877848
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03877848 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
EluNIR Ridaforolimus Eluting Coronary Stent System in Patients at High Bleeding Risk (HBR)- EluNIR HBR Study
Lead sponsor
Medinol Ltd.
Phase
Observational
Overall status
Completed
Start date
May 6, 2019
Completion date
June 10, 2021
Enrollment
319 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

coronary stenosis